TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18375320
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (7%) (1.2 mL/kg)
Study: 18375320
Drug: Saline (0.9%)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (0.9%) (1.2 mL/kg)
Study: 15750756
Drug: Interferon alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha-2a plus ribavirin 1,000/1,200 mg
Study: 15750756
Drug: Interferon alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha-2a plus ribavirin 600 mg
Study: 3933617
Drug: Seven day
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven day course of amoxycillin 125 mg three times a day
Study: 3933617
Drug: Two day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two day course of amoxycillin 750 mg twice a day
Study: 31192975
Drug: Tigecycline 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline 1.2 mg/kg every 12 hours for children 8-11 years and 50 mg every 12 hours for children 12 to <18 years
Study: 18001407
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Study: 18001407
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Study: 18001407
Drug: rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Study: 18001407
Drug: esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole 40 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Study: 15143718
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with Chaihu Droplet pill (CHDP) and Huoxiang Zhengqi Droplet pill (HZDP) for 13 days
Study: 9881239
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (group B, n = 46)
Study: 9881239
Drug: Animal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Animal insulin (group A, n = 48)
Study: 7674870
Drug: Choline bitartrate
Normalized name: Choline Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline bitartrate (2.43 g)
Study: 2282973
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ampicillin plus 1 g sulbactam, given intravenously every 6 h
Study: 2282973
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin, given intravenously every 6 h
Study: 6111570
Drug: Oxycodone compound
Normalized name: oxyCODONE compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone compound (equivalent to 12.5 mg morphine)
Study: 25433727
Drug: Hands-on gel
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hands-on gel phantom training
Study: 23650124
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin 8% (Qutenza)
Study: 23650124
Drug: Topical low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical low-dose capsaicin 0.04% (active control)
Study: 15464767
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (200 microg/tablet, 2 tablets)
Study: 15464767
Drug: Intravenous methylergometrine
Normalized name: methylergometrine
DrugBank: Methylergometrine (DB00353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylergometrine (200 microg, 1 ml)
Study: 7820061
Drug: Splenectomy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splenectomy after complete response (CR) to alpha interferon (IFN) therapy
Study: 7820061
Drug: Alpha interferon
Normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha interferon (IFN) therapy
Study: 2040042
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg qd
Study: 31583253
Drug: Trigonella foenum‐graecum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigonella foenum‐graecum seed powder solution (25g orally twice a day for one month)
Study: 28756607
Drug: Dralitem® (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dralitem® (200 mg/m2)
Study: 28756607
Drug: Temodal® (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temodal® (200 mg/m2)
Study: 15042607
Drug: Screening (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening (serum PSA measurement and digital rectal examination)
Study: 8140488
Drug: Single 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 g dose of azithromycin
Study: 8140488
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg doxycycline twice daily for seven days
Study: 11225459
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution
Study: 30309406
Drug: ASPMCG solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASPMCG solution
Study: 27581533
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg telmisartan/5 mg amlodipine/12.5 mg hydrochlorothiazide (T80/A5/H12.5)
Study: 27581533
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg telmisartan/12.5 mg hydrochlorothiazide (T80/H12.5)
Study: 12607205
Drug: Fluoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40 mg/day) plus misoprostol (500 mg/day)
Study: 12607205
Drug: Indomethacine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacine (100 mg/day) plus misoprostol (500 mg/day)
Study: 12607205
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus misoprostol (500 mg/day)
Study: 1598427
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg/day for 30 days)
Study: 1598427
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg/day for 30 days)
Study: 1598427
Drug: Control (healthy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (healthy volunteers without treatment)
Study: 6144128
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg zimelidine each morning for 5 days
Study: 6144128
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg temazepam 2 h after zimelidine
Study: 30102413
Drug: Selumetinib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (75 mg twice daily) plus docetaxel
Study: 23406027
Drug: Selumetinib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (75 mg twice daily)
Study: 26932437
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (CRT) using a moderate radiation dose weekly combined with carboplatin and paclitaxel followed by surgery
Study: 8574252
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol 30 micrograms and gestodene 75 micrograms (oral contraceptives)
Study: 2150580
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg/day orally)
Study: 758493
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dihydroergotamine and heparin
Study: 27402913
Drug: Mercaptopurine treatment
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mercaptopurine treatment
Study: 27402913
Drug: Concurrent anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent anti-TNF therapy
Study: 12821551
Drug: EP-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-guided therapy
Study: 11432797
Drug: Initial daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial daily dosing of 6 MU Interferon-alpha-2a daily for 12 weeks, then reduced to 6 MU three times weekly until week 12 and 3 MU three times weekly thereafter until month 12.
Study: 11432797
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with 5 MU Interferon-alpha-2b or 6 MU Interferon-alpha-2a three times a week for 12 months.
Study: 9730559
Drug: Low-grade CMV
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-grade CMV infection (no treatment)
Study: 7982253
Drug: Brodimoprim 200
Normalized name: brodimoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim 200 mg tablets once a day (400 mg on the first day as a loading dose)
Study: 7982253
Drug: Cephalexin 500
Normalized name: cephalexin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 500 mg tablets three times a day for 8 to 12 days
Study: 808445
Drug: Topical disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical disodium cromoglycate (DSCG) 200 mg by enema twice daily and 100 mg orally three times daily
Study: 30642293
Drug: Lanreotide depot/autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide depot/autogel 120 mg every 4 weeks for 96 weeks
Study: 25096818
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (DHA and EPA) - 2 MorDHA capsules per day for 14 months
Study: 24199774
Drug: Treated tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated tea (600 mL of oolong tea treated by three Buddhist monks)
Study: 24199774
Drug: Untreated tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated tea (600 mL of ordinary oolong tea)
Study: 21593492
Drug: Daily presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily presentation of macaroni and cheese meal for 1 week
Study: 21593492
Drug: Once-weekly presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly presentation of macaroni and cheese meal for 5 weeks
Study: 17397033
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of androgen suppression therapy (AST) plus external beam radiation therapy (RT)
Study: 17397033
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of androgen suppression therapy (AST) plus external beam radiation therapy (RT)
Study: 12547878
Drug: Maggot therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maggot therapy
Study: 10703801
Drug: Phenobarbital (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (20 mg/kg)
Study: 10703801
Drug: Phenobarbital (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (20 mg/kg) plus three or more doses of diazepam
Study: 30464372
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (thermal therapy)
Study: 23804546
Drug: Actiponin (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actiponin (450 mg day(-1))
Study: 22739693
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) coadministered with trivalent inactivated influenza vaccine (TIV)
Study: 10376904
Drug: IV administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of metformin (25 mg/kg)
Study: 10376904
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of metformin (25 mg/kg)
Study: 10376904
Drug: Computer simulations
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer simulations of oral metformin (2 mg/kg every 12 hours)
Study: 8901787
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (15 mg/d) for 3 months
Study: 6181653
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg femoxetine daily for 6 weeks
Study: 6181653
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg desipramine daily for 6 weeks
Study: 29326015
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin administered in the abdomen
Study: 29326015
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin administered in the arm
Study: 22741618
Drug: Artemisinin-piperaquine (Artequick®)
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-piperaquine (Artequick®) - 2.8 mg/kg artemisinin plus 17.1 mg/kg piperaquine per day for 2 days
Study: 22741618
Drug: Artesunate-amodiaquine (Coarsucam™)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artesunate-amodiaquine (Coarsucam™) - 4.7 mg/kg artesunate plus 12.6 mg/kg amodiaquine per day for 3 days
Study: 17459695
Drug: Ketorolac 15
Normalized name: ketorolac 15.75 mg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 15 mg i.v. bolus 20 min before induction, followed by an infusion of 7.5 mg/h
Study: 10095154
Drug: Octreotide 25
Normalized name: octreotide 2500 mcg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 25 microgram/h intravenously (continuous infusion)
Study: 10095154
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 microgram/h intravenously (continuous infusion)
Study: 8690630
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy at 4 months after surgery for pre/perimenopausal patients
Study: 8690630
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy at 7 months after surgery for pre/perimenopausal patients
Study: 8690630
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy at 2 months after surgery for postmenopausal patients
Study: 8690630
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy at 4 months after surgery for postmenopausal patients
Study: 8690630
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy after three or six cycles of CMF for pre/perimenopausal women
Study: 8690630
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy after no cycles or three cycles of CMF for postmenopausal women
Study: 31652220
Drug: Red LED
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red LED photomodulation (633 nm) for 20 minutes at 4 weekly sessions (105 mW/cm, 126 J/cm)
Study: 28784510
Drug: Synbiotic beverage
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic beverage (150mL daily)
Study: 28784510
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (150mL daily)
Study: 25660828
Drug: Wearable pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable pulsed electromagnetic field (PEMF) therapy device
Study: 19775034
Drug: Opioid-sparing postoperative
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-sparing postoperative analgesia protocol (tramadol patient‐controlled analgesia, parecoxib and rescue‐only morphine)
Study: 19775034
Drug: Standard morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard morphine patient‐controlled analgesia
Study: 17288687
Drug: EPs 7630
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPs 7630 solution (30 drops three times daily for 7 days)
Study: 12807337
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 drops three times daily for 7 days)
Study: 17288687
Drug: EPs 7630
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPs 7630 solution
Study: 8819128
Drug: Intralesional GM-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional GM-CSF (15-50 mg doses)
Study: 20041960
Drug: Conventional hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional hemodialysis (CvHD) thrice weekly for 6 months
Study: 15661451
Drug: High TSH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High TSH values (TSH >= 10 mU/L)
Study: 15661451
Drug: Normal TSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal TSH values (0.2-4 mU/L)
Study: 12067084
Drug: Real acupuncture
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real acupuncture treatment (three times per week for four weeks)
Study: 12067084
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment (three times per week for four weeks)
Study: 15321137
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/ml (group B)
Study: 15321137
Drug: Bupivacaine 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.625 mg/ml + sufentanil 1 microg/ml (group BS)
Study: 15321137
Drug: Bupivacaine 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.625 mg/ml + sufentanil 1 microg/ml + epinephrine 1 microg/ml (group BSE)
Study: 7734157
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally twice a day (Group A)
Study: 7734157
Drug: Ciprofloxacin drops
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin drops in saline solution locally twice a day (Group B)
Study: 2291745
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (P)
Study: 2291745
Drug: Control preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control preparation (R)
Study: 21842003
Drug: 1-stage early
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-stage early loaded implants
Study: 21842003
Drug: 2-stage early
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-stage early loaded implants
Study: 20715726
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of lactated Ringer's solution (20 ml.kg(‐1), n=40)
Study: 20715726
Drug: 4% succinylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% succinylated gelatin solution (500 ml, n=40)
Study: 20715726
Drug: Ephedrine infusion
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine infusion (1.25 mg.minute(‐1)) plus lactated Ringer's solution (1000 ml, n=40)
Study: 20715726
Drug: Ephedrine infusion
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine infusion with crystalloid co-load
Study: 17396039
Drug: irinotecan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 80 mg/m2 followed by FA 500 mg/m2 and 5-FU 2,000 mg/m2 24 h weekly for 6 weeks
Study: 17396039
Drug: irinotecan 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 125 mg/m2 weekly for 4 weeks
Study: 11952192
Drug: Behavioral couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral couples therapy (BCT; n = 37)
Study: 11952192
Drug: Individual-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual-based treatment (IBT; n = 38)
Study: 8561836
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg cycloserine
Study: 8561836
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cycloserine
Study: 8561836
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg cycloserine
Study: 2230895
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy (Control) (n = 198)
Study: 26262795
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (7.5 g of 1% testosterone gel daily for 3 years)
Study: 26262795
Drug: Placebo (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gel packets daily for 3 years)
Study: 19210644
Drug: Suplatast tosilate
Normalized name: Edoxaban Tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suplatast tosilate (6 mg/kg daily)
Study: 19210644
Drug: Ketotifen fumarate
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen fumarate (0.06 mg/kg daily)
Study: 15034704
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg once daily for 7 days